Professor, Psychiatry, Baylor College of Medicine
Neurology
Dr. Thomas R. Kosten, MD
|
|
Give Review
Thomas R. Kosten is an expert in the field of Neurology. He attended Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University has a rank of 18 in research and a 49 in primary care He has 1 awards "Whos Who in Medicine and Healthcare". Thomas Kosten is a published physician as well. He has 102 publications published. The latest was: Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population.
Publications
- Next Generation Programmable Bio-Nano-Chip System for On-Site Detection in Oral Fluids.
- Pharmacologic management of comorbid post-traumatic stress disorder and addictions.
- Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine.
- Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy.
- Inhibitory behavioral control: a stochastic dynamic causal modeling study using network discovery analysis.
- Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.
- Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization.
- The future potential for cocaine vaccines.
- Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China.
- The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.
- Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.
- Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial.
- Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.
- Pharmacotherapy for stimulant-related disorders.
- Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia.
- Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.
- Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
- Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study.
- A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats.
- The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.
- Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and α1A-adrenoceptor gene variation.
- Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients.
- A vaccine against methamphetamine attenuates its behavioral effects in mice.
- Cognitive Function, Plasma MnSOD Activity, and MnSOD Ala-9Val Polymorphism in Patients With Schizophrenia and Normal Controls.
- Can you vaccinate against substance abuse?
- Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study.
- ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.
- Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.
- Spontaneous Development of IgM Anti-Cocaine Antibodies in Habitual Cocaine Users: Effect on IgG Antibody Responses to a Cocaine Cholera Toxin B Conjugate Vaccine.
- Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans.
- Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls.
- Vaccines against stimulants: Cocaine and Methamphetamine.
- DBH gene as predictor of response in a cocaine vaccine clinical trial.
- Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls.
- The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency.
- BDNF Val66Met variant and smoking in a Chinese population.
- The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.
- The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial.
- Alpha Oscillations in Response to Affective and Cigarette-Related Stimuli in Smokers.
- Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase.
- Probing cocaine-antibody interactions in buffer and human serum.
- Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba.
- Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia.
- Association between TNF-? promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia.
- The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders.
- Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms.
- The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.
- Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia.
- Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.
- Smoking and tardive dyskinesia in male patients with chronic schizophrenia.
- Stress and addiction.
- Prescription pain medication dependence.
- Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia.
- Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.
- Spirituality and Confidence to Resist Substance Use Among Celebrate Recovery Participants.
- Novel pharmacotherapeutic treatments for cocaine addiction.
- Active immunotherapy for the Treatment of Cocaine Dependence.
- Stress enhances retrieval of drug-related memories in abstinent heroin addicts.
- Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
- Aripiprazole treatment of risperidone-induced hyperprolactinemia.
- Circadian alteration in neurobiology during 30 days of abstinence in heroin users.
- Vaccines for cocaine abuse.
- Traditional medicine in the treatment of drug addiction.
- Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
- Diurnal variation in cue-induced responses among protracted abstinent heroin users.
- Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chines...
- Substance abuse vaccines.
- BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia.
- Pharmacogenetic treatments for drug addiction: alcohol and opiates.
- New hot topics sections: 1. China's new march forward in addiction treatment: methadone for the masses. 2. Issues in formulating DSM V.
- Serum cortisol secretion during heroin abstinence is elevated only nocturnally.
- Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study.
- The future of vaccines in the management of addictive disorders.
- Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia.
- Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.
- Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia.
- Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients.
- Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.
- Human laboratory and neuroimaging studies in substance use disorders: developing new treatment approaches.
- Pharmacotherapeutic environments for substance use disorders.
- Treatment outcome predictors for cocaine dependence.
- Association of spirituality and sobriety during a behavioral spirituality intervention for Twelve Step (TS) recovery.
- Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty.
- Genetics of dopamine and its contribution to cocaine addiction.
- Pharmacotherapy for addictions: partnering with contingency management.
- Cue-induced brain activity changes and relapse in cocaine-dependent patients.
- Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
- Tiagabine affects the subjective responses to cocaine in humans.
- Vaccine pharmacotherapy for the treatment of cocaine dependence.
- What are America's opportunities for harm reduction strategies in opiate dependence?
- Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study.
- The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects.
- Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
- Pharmacologic management of relapse prevention in addictive disorders.
- New medication strategies for comorbid substance use and bipolar affective disorders.
- Perfusion abnormalities and decision making in cocaine dependence.
- Consensus statement on office-based treatment of opioid dependence using buprenorphine.
- Effects of progesterone treatment on cocaine responses in male and female cocaine users.
- Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers.
- Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population.
- Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia.
Schools
Weill Cornell Medical College
Greenwich Yale University
Yale
Doctors Specialties
- Addiction Psychiatry
- Neurology
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Education
-
Yale-New Haven Hospital -
Yale University School of Medicine -
Weill Cornell Medical College of Cornell University
Hospital
-
University of Texas M.D. Anderson Cancer Center -
Michael E. DeBakey Veterans Affairs Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Randall C. Edgell, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven M. Croft, MD |
|
Dr. George A. Lopez, MD |
|
|
Dr. Donna D. Yi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shivika Chandra, MD |
|
|
Dr. Xiangping Li, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaofan Li, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammadreza Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sreepadma P. Sonty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Zishan A. Samiuddin, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paolo M. Moretti, MD
This Doctor is OpenDoctor Recommended.
|